Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Rectal Neoplasms 3Esophageal Neoplasms 3Colonic Neoplasms 3Breast Neoplasms 3Stomach Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Neoplasms 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Solid Tumors Harboring NTRK Fusion 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Papillomavirus Infections 1Ovarian Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Insulin-Like Growth Factor I, Resistance To 1Gliosarcoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Brain Neoplasms 1Advanced Solid Tumor 1

Interventions

Sorafenib 222lenvatinib 147Bevacizumab 131Nivolumab 87atezolizumab 81pembrolizumab 74Radiosurgery 71durvalumab 63sintilimab 61Oxaliplatin 60Fluorouracil 56Doxorubicin 47tislelizumab 46apatinib 45Radiofrequency Ablation 44Hepatectomy 43camrelizumab 41Leucovorin 41Radiotherapy 40tremelimumab 37Magnetic Resonance Spectroscopy 36regorafenib 34Capecitabine 30Immune Checkpoint Inhibitors 29Folfox protocol 29Cisplatin 28cabozantinib 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Receptor Protein-Tyrosine Kinases × Clear all
NCT00956436 2013-09-16

Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)

Biogen

Phase 1 Completed
40 enrolled
Gastrointestinal

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Hepatocellular, Liver Neoplasms

NCT01266707 2010-12-24

Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma

Fukushima Medical University

Phase 1 Unknown
9 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡